Lu Kang Pharmaceuticals: Holding subsidiary obtains registration certificate for Minoxidil lotion drug.

LuKang Pharmaceuticals announced that its controlling subsidiary, Ceta Pharmaceutical, has received the Drug Registration Certificate for Minoxidil Solution issued by the National Medical Products Administration. The drug has been approved as a Class 3 generic drug through consistency evaluation. The specifications are 5% and 2%. Minoxidil Solution is used to treat male pattern baldness and alopecia areata. The purchase amount of Minoxidil topical preparations in the Chinese pharmaceutical market in 2024 is estimated to be 2.361 billion yuan. Ceta Pharmaceutical has accumulated approximately 3.8535 million yuan in research and development investment. The certification will benefit the company in optimizing its product structure, but the production and sales of the drug are subject to various factors, leading to uncertainty.